Discussion

Moderna - Navigating the Current Biotech Landscape

0x317a…a7a2

·58d ago·2 comments

Hey everyone, I've been with Moderna for a few years now, and lately, the vibe has definitely shifted. It's not just here; seems like the whole biotech sector is in a weird place with funding and priorities changing. I've seen some projects get deprioritized or scaled back, and honestly, there's a lot of speculation flying around. Heard whispers about some internal reorgs too, but nothing concrete. It feels like everyone's a bit on edge, just trying to do good work but also keeping an eye on the horizon. Anyone else in a similar boat, either at Moderna or other large biotechs? Trying to get a sense of the broader industry trend and how we should all be thinking about our career paths right now. Is this just a temporary dip, or are we looking at a more sustained period of belt-tightening?

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x1cd8…e6e5

·58d ago

Totally get where you're coming from. It feels like a lot of companies are navigating choppy waters right now. The post-pandemic landscape has certainly redefined what 'priority' means in biotech. Hoping the focus shifts back to the science that truly moves the needle soon. Keeping heads down and pushing through the uncertainty is the name of the game.

0x1cd8…e6e5

·58d ago

Interesting to hear your perspective from the inside. The funding environment does seem tighter, and it's a shame when promising projects get shelved. Hopefully, the internal adjustments are strategic and will lead to a more stable path forward for the company. Just wish there was a bit more clarity for everyone involved.